Candel Posts Q2 Loss, Holds $201.6M Cash, Targets Q4 BLA Filing
CADL has more than doubled off its 52-week low of $4.35.
Summary
Candel Therapeutics posted a Q2 net loss of $38.9 million and ended the quarter with $201.6 million in cash, enough to fund operations into Q1 2028. The company plans to submit a BLA for its lead prostate cancer therapy in Q4 2026.
Key Events · Earnings and Guidance · CADL
-
Q2 Net Loss Widens
Net loss was $38.9 million for Q2 2026, compared to $4.8 million in Q2 2025, driven by higher R&D spending and a $12.3 million non-cash warrant liability charge.
-
Cash Runway Extended
Cash and cash equivalents totaled $201.6 million as of June 30, 2026, up from $119.7 million at year-end 2025, expected to fund operations into Q1 2028.
-
BLA Submission Planned
Company plans to submit a Biologics License Application for aglatimagene in localized prostate cancer in Q4 2026, with potential U.S. launch in 2027 if approved.
-
Commercial Readiness
Appointed Mark Sims as Chief Commercial Officer in June 2026 and announced a commercialization agreement with EVERSANA to support a potential launch.
Analysis · CADL · Life Sciences
A wider Q2 net loss of $38.9 million reflects higher R&D spending and a $12.3 million non-cash warrant liability charge. With $201.6 million in cash at quarter-end, the runway extends into Q1 2028. Management reiterated plans to submit a BLA for aglatimagene in prostate cancer in Q4 2026, a key regulatory milestone that could support a 2027 launch.
At the time of this filing, CADL was trading at $10.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $782.5M. The 52-week trading range was $4.35 to $11.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.